State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Oncogene. 2022 Jul;41(28):3587-3598. doi: 10.1038/s41388-022-02371-1. Epub 2022 Jun 6.
Transcription dysregulation is a salient characteristic of bladder cancer (BC), but no appropriate therapeutic target for it has been established. Here, we found that heterogeneous downregulation of histone H4 transcription factor (HINFP) was associated with senescence in BC tissues and that lower HINFP expression could predict an unfavorable outcome in BC patients. Knockout of HINFP transcriptionally inhibited H1F0 and H1FX to trigger DNA damage, consequently inducing cell senescence to repress the proliferation and growth of BC cells. However, the senescence-associated secretory phenotype, characterized by increases in MMP1/3, enhances the invasion and metastasis of non-senescent BC cells. Histone deacetylase inhibitors (HDACis) could efficiently eliminate the senescent cells induced by HINFP knockout to suppress the invasion and metastasis of BC cells. Our study suggests that HDACis, widely used in multiple cancer types in a clinical context, may also benefit BC patients with metastases induced by cell senescence.
转录失调是膀胱癌 (BC) 的一个显著特征,但尚未确定针对它的合适治疗靶点。在这里,我们发现组蛋白 H4 转录因子 (HINFP) 的异质性下调与 BC 组织中的衰老有关,并且较低的 HINFP 表达可以预测 BC 患者的不良预后。HINFP 的敲除转录抑制 H1F0 和 H1FX 以引发 DNA 损伤,从而诱导细胞衰老以抑制 BC 细胞的增殖和生长。然而,衰老相关的分泌表型,其特征是 MMP1/3 的增加,增强了非衰老 BC 细胞的侵袭和转移。组蛋白去乙酰化酶抑制剂 (HDACi) 可以有效地消除由 HINFP 敲除诱导的衰老细胞,从而抑制 BC 细胞的侵袭和转移。我们的研究表明,HDACi 在临床背景下广泛用于多种癌症类型,也可能使由细胞衰老引起转移的 BC 患者受益。